Physician profile
Barbara E Moore
NPI 1831124932
$9,850.03
in general payments reported to CMS, 2019-2025
48 companies · $2,402 in 2025
The $2,402 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,399 · 2022: $1,624 · 2023: $1,724 · 2024: $1,702 · 2025: $2,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,827.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,054.21 | 2021-2025 | |
| Novo Nordisk INC | $1,038.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,025.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $913.03 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $709.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.54 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $538.67 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $467.06 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $390.40 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $375.65 | 2021-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $244.73 | 2021-2025 | |
| Corium, LLC | $203.95 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $189.27 | 2021-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $177.53 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $175.96 | 2025 | Sunosi, Symbravo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.